EUCTR2014-002189-64-HU进行中（未招募）不适用
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =18 years male or female.
- •2. Histological confirmation of SCLC.
- •3. Relapsed or refractory to no more than 1 course of a systemic therapy regimen and is incurable
- •by either surgery or radiation.
- •4. Capable of providing informed consent and complying with trial procedures.
- •5. ECOG PS 0-2.
- •6. Life expectancy >8 weeks.
- •7. Measurable tumor lesions according to RECIST 1.1 criteria.
- •8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.)
- •9. Males and their female partner(s) of child-bearing potential must use 2 forms of effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the last menstrual period of the female partner during the study treatment and for 6 months after the final dose of study treatment.
- •10. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
- •11. Accessibility to the site that ensures the subject will be able to keep all study-related appointments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 66
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 66
排除标准
- •1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin.
- •2. Prior treatment with topotecan.
- •3. Palliative surgery and/or radiation treatment < 14 days prior to date of randomization.
- •4. Exposure to any investigational agent within 30 days of date of randomization.
- •5. Exposure to any systemic chemotherapy within 21 days of date of randomization.
- •6. Active (symptomatic) central nervous system (CNS) metastasis.
- •7. History of other malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for =3 years.
- •8. Laboratory values: Screening serum creatinine >1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) >3×ULN or >5×ULN if liver metastases are present, total bilirubin >2×ULN, absolute neutrophil count (ANC) <1,500/mm3, platelet concentration <100,000/mm3, hemoglobin <9 g/dL, albumin <2 gm/dL.
- •9. Anion gap >16 meq/L or arterial blood pH <7.30
- •10. Clinically evident congestive heart failure (CHF) > class II of the New York Heart Association (NYHA) guidelines.
- •11. Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
- •12. Baseline QTc >470 msec measured by Fridericia’s formula (QTcF) and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed.
- •13. History or signs of active coronary artery disease with angina pectoris within the last 6 months.
- •14. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution’s lower limit of predicted normal.
- •15. Known history of HIV infection.
- •16. Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or antifungals.
- •17. Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar, ketoconazole, ritonavir, saquinavir.
- •18. Major surgery within 30 days prior to date of randomization.
- •19. Substance abuse or any condition that might interfere with the subject’s participation in the study or in the evaluation of the study results.
- •20. Any condition that is unstable and could jeopardize the subject’s participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A study to compare how safe INNO-206 is and how well it works against Doxorubicin in patients with soft tissue sarcomaEUCTR2011-004927-11-HUCytRx Corporation105
尚未招募
2 期
A study to compare how safe INNO-206 is and how well it works against Doxorubicin in patient with soft tissue sarcomaCTRI/2012/10/003068CytRx Corporation105
进行中（未招募）
1 期
A study to compare how safe Aldoxorubicin is and how well it works against Topotecan in patients with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior ChemotherapyMetastatic Small Cell Lung CancerMedDRA version: 18.0Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002189-64-ESCytRx Corporation132
进行中（未招募）
1 期
A study to compare how safe Aldoxorubicin is and how well it works against Topotecan in patients with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior ChemotherapyMetastatic Small Cell Lung CancerEUCTR2014-002189-64-ITCytRx Corporation132
招募中
2 期
A Randomized Phase 2 Study of TRK-950 when Used in Combination withRamucirumab and Paclitaxel in Patients with Gastric CancerGastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaJPRN-jRCT2031230319Mori Yoshitaka146